跳至主要内容
临床试验/ITMCTR2100004871
ITMCTR2100004871已完成4 期

The efficacy, safety and quality of life of tandospirone and shuganjieyu capsule in the treatment of comorbid anxiety and depression of epilepsy

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital0 个研究点开始时间: 待定最近更新:

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. Aged 18 to 70 years;
  • 2. The clinical manifestations and EEG changes of the patients were in line with the 2017 epilepsy diagnostic criteria formulated by the International Anti-Epilepsy Union (ILAE), and epilepsy was classified;
  • 3. Antiepileptic drugs remained unchanged in the two groups;
  • 4. According to the relevant diagnostic points of depression and anxiety in the 10th edition of the International Classification of Diseases (ICD-10), one professional neurologist and one psychiatrist respectively completed the relevant scale, with CNDDIE score of > 12 points and GAD-7 score of > 6 points.

排除标准

  • 1. Epileptic status or non-epileptic seizure;
  • 2. Patients with severe depression or suicidal tendencies;
  • 3. Previous depression and anxiety, history and family history of mental illness, severe mental illness or being under treatment;
  • 4. Pregnant or lactating women;
  • 5. Patients who have taken anti-depressant and anxiety-related drugs or are allergic to the two intervention drugs used in this study within the last 2 weeks.

研究者

相似试验